Decreased-Amyloid 1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease
暂无分享,去创建一个
Trey Sunderland | J. Bartko | T. Sunderland | R. Cohen | Nadeem Mirza | Karen T. Putnam | Gary Linker | Judy Bergeson | John J. Bartko | Robert M. Cohen | G. Linker | Nadeem Mirza | K. Putnam | L. Kimmel | J. Bergeson | G. Manetti | M. Zimmermann | B. Tang | Matthew Zimmermann | Brian Tang | David L. Friedman | Lida H. Kimmel | MA | Guy J. Manetti | Ma | Judy Bergeson
[1] Jeffrey L. Cummings,et al. Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[2] H. Vanderstichele,et al. Cerebrospinal beta-amyloid (1–42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline , 2000, Neuroscience Letters.
[3] M. Neumann,et al. Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies , 2000, Neurology.
[4] Jacob Cohen. Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.
[5] M. Rossor,et al. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease , 1999, Neuroscience Letters.
[6] H. Arai,et al. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia , 1998, Neuroscience Letters.
[7] M. Mendez,et al. Clinically Diagnosed Alzheimer Disease: Neuropathologic Findings in 650 Cases , 1992, Alzheimer disease and associated disorders.
[8] K. Blennow,et al. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[9] L. Chang,et al. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. , 1995, Annals of clinical and laboratory science.
[10] J. Kornhuber,et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. , 2000, Neurology.
[11] J. Morris,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XIII. , 1996, Neurology.
[12] T. Lehtimäki,et al. Longitudinal stability of CSF tau levels in Alzheimer patients , 1999, Biological Psychiatry.
[13] H. Wiśniewski,et al. Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain. , 1996, Archives of neurology.
[14] Katharina Buerger,et al. Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease , 2001, Annals of neurology.
[15] B. Miller,et al. CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[16] K. Blennow,et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. , 1999, Neurology.
[17] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[18] Hilkka Soininen,et al. Relationship between apoE genotype and CSF β-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease , 2000, Neurobiology of Aging.
[19] B Engvall,et al. Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression , 1999, Annals of neurology.
[20] Leo Breiman,et al. Classification and Regression Trees , 1984 .
[21] D. Galasko,et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. , 1995, Annals of neurology.
[22] H. Chui,et al. Multicenter clinicopathological correlation in dementia. , 1995, The American journal of psychiatry.
[23] E. Wolters,et al. Concentrations of amyloid β protein in cerebrospinal fluid of patients with alzheimer's disease , 1995, Annals of neurology.
[24] K. Blennow,et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.
[25] K. Blennow,et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. , 2001, Clinical chemistry.
[26] Á. Hernanz,et al. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[27] I. Zalonis,et al. CSF tau protein and β‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population , 2003, European journal of neurology.
[28] Hiroyuki Arai,et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease , 1999, Neuroscience Letters.
[29] J. Trojanowski,et al. Effect of Genetic Risk Factors and Disease Progression on the Cerebrospinal Fluid Tau Levels in Alzheimer's Disease , 1997, Journal of the American Geriatrics Society.
[30] B. J. Winer. Statistical Principles in Experimental Design , 1992 .
[31] S. Hirai,et al. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. , 1997, Journal of the neurological sciences.
[32] Y. Nakamura,et al. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. , 1998, Methods and findings in experimental and clinical pharmacology.
[33] C. P. Hughes,et al. A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.
[34] J. Kaye,et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. , 1998, Archives of neurology.
[35] Robert Rosenthal,et al. Judgment Studies: Design, Analysis, and Meta-Analysis , 1987 .
[36] K. Blennow,et al. Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[37] S. Hirai,et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau , 1995, Neuroscience Letters.
[38] L. Wahlund,et al. Tau protein in cerebrospinal fluid from semantic dementia patients , 2000, Neuroscience Letters.
[39] L. Chang,et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease , 1995, Neurology.
[40] S. Rapoport,et al. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 , 2001, Annals of neurology.
[41] K. Blennow,et al. Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds , 2003, Dementia and Geriatric Cognitive Disorders.
[42] S. Rapoport,et al. Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls , 1999, Neuroscience Letters.
[43] K. Blennow,et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study , 1998, Journal of neurology, neurosurgery, and psychiatry.
[44] C. Hock,et al. Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease , 1997, Neuroscience Letters.
[45] D. Sackett,et al. The architecture of diagnostic research , 2002, BMJ : British Medical Journal.
[46] J. Growdon,et al. Cerebrospinal fluid levels of amyloid β‐protein in alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein e genotype , 1995, Annals of neurology.
[47] P. Deyn,et al. Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.
[48] K. Blennow,et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. , 2002, Dementia and Geriatric Cognitive Disorders.
[49] D. Selkoe,et al. The origins of Alzheimer disease: a is for amyloid. , 2000, JAMA.
[50] A. Kurz,et al. Tau Protein in Cerebrospinal Fluid Is Significantly Increased at the Earliest Clinical Stage of Alzheimer Disease , 1998, Alzheimer disease and associated disorders.
[51] Giovanni B. Frisoni,et al. Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .
[52] K. Blennow,et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.
[53] C. Hock,et al. Increased levels of τ protein in cerebrospinal fluid of patients with alzheimer's disease—correlation with degree of cognitive impairment , 1995, Annals of neurology.
[54] P. Vermersch,et al. Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. , 1999, Neuroreport.
[55] S. Hirai,et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. , 1998, Journal of the neurological sciences.
[56] H. Yamanouchi,et al. Access www.neurology.org now for full-text articles , 2001, Neurology.
[57] K. Blennow,et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. , 1999, Archives of neurology.
[58] J. Yesavage,et al. Combined assessment of tau and neuronal thread protein in Alzheimer’s disease CSF , 2000, Neurology.
[59] K. Yanagisawa,et al. Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients. , 2000, European Neurology.
[60] J. Trojanowski,et al. Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease , 1995, Annals of neurology.
[61] J. Growdon,et al. Cerebrospinal Fluid Levels of Amyloid Precursor Protein and Amyloid β-Peptide in Alzheimer’s Disease and Major Depression – Inverse Correlation with Dementia Severity , 1998, European Neurology.
[62] S. Younkin,et al. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. , 1994, Annals of Neurology.
[63] J. Morris,et al. Relationships Among Cerebrospinal Fluid Biomarkers in Dementia of the Alzheimer Type , 2002, Alzheimer disease and associated disorders.
[64] M. Vandermeeren,et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. , 1993, Journal of neurochemistry.
[65] K. Blennow,et al. CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging , 2000, Journal of Neural Transmission.
[66] B. Reisberg,et al. The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.
[67] E. Matsubara,et al. Cerebrospinal fluid tau in dementia disorders , 2000, Neurobiology of Aging.
[68] S. Hirai,et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. , 1998, Annals of neurology.
[69] H. Wiśniewski,et al. Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .
[70] R. Lewis. An Introduction to Classification and Regression Tree (CART) Analysis , 2000 .